|
NL62140C
(enExample)
*
|
1942-12-16 |
|
|
|
|
DE2104179C3
(de)
|
1971-01-29 |
1980-10-02 |
Knoll Ag, 6700 Ludwigshafen |
exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
|
|
FR2155927A1
(en)
|
1971-10-15 |
1973-05-25 |
Synthelabo |
1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
|
|
FR2168881A1
(en)
|
1972-01-25 |
1973-09-07 |
Synthelabo |
Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
|
|
FR2208649A1
(en)
|
1972-12-01 |
1974-06-28 |
Synthelabo |
1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
|
|
GB8334494D0
(en)
*
|
1983-12-24 |
1984-02-01 |
Tanabe Seiyaku Co |
Carbostyril derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9003057D0
(sv)
|
1990-09-26 |
1990-09-26 |
Astra Ab |
New process
|
|
KR20000029703A
(ko)
|
1996-07-29 |
2000-05-25 |
존 헤덴스트룀 |
아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법
|
|
DE59709927D1
(de)
|
1996-11-11 |
2003-05-28 |
Noe Christian |
Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels
|
|
US6613795B2
(en)
*
|
1996-11-11 |
2003-09-02 |
Christian Noe |
Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
|
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
GB0015876D0
(en)
|
2000-06-28 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
|
NZ526674A
(en)
|
2000-12-28 |
2005-03-24 |
Almirall Prodesfarma Ag |
Novel quinuclidine derivatives and medicinal compositions containing the same
|
|
US7045658B2
(en)
|
2001-03-22 |
2006-05-16 |
Glaxo Group Limited |
Formailide derivatives as beta2-adrenoreceptor agonists
|
|
WO2002096855A2
(en)
|
2001-04-03 |
2002-12-05 |
Aryx Therapeutics |
Anticholinergic compounds and methods of use
|
|
CA2445839A1
(en)
|
2001-04-30 |
2002-11-07 |
Glaxo Group Limited |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
|
TWI249515B
(en)
|
2001-11-13 |
2006-02-21 |
Theravance Inc |
Aryl aniline beta2 adrenergic receptor agonists
|
|
US20030229058A1
(en)
|
2001-11-13 |
2003-12-11 |
Moran Edmund J. |
Aryl aniline beta2 adrenergic receptor agonists
|
|
DE10216333A1
(de)
|
2002-04-13 |
2003-10-30 |
Boehringer Ingelheim Pharma |
Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
|
ES2206021B1
(es)
|
2002-04-16 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de pirrolidinio.
|
|
DE60320439T2
(de)
|
2002-10-11 |
2009-05-20 |
Pfizer Inc. |
INDOLDERIVATE ALS ß2-AGONISTEN
|
|
US7056916B2
(en)
*
|
2002-11-15 |
2006-06-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Medicaments for the treatment of chronic obstructive pulmonary disease
|
|
AR044134A1
(es)
*
|
2003-05-02 |
2005-08-24 |
Novartis Ag |
Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
|
|
AR044851A1
(es)
|
2003-06-24 |
2005-10-05 |
Novartis Ag |
Compuestos heterociclicos, antagonistas del receptor m3 muscarinico
|
|
EP1684767A1
(en)
|
2003-11-03 |
2006-08-02 |
Norton Healthcare Limited |
Soft steroid compositions for use in dry powder inhalers
|
|
US20080027094A1
(en)
|
2004-08-30 |
2008-01-31 |
Ono Pharmaceutical Co., Ltd. |
Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient
|
|
EP1797040A1
(en)
|
2004-09-29 |
2007-06-20 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
MX2007004862A
(es)
|
2004-10-29 |
2007-05-09 |
Astrazeneca Ab |
Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
|
|
GB0424284D0
(en)
*
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0428416D0
(en)
|
2004-12-24 |
2005-02-02 |
Novartis Ag |
Organic compounds
|
|
TW200722418A
(en)
|
2005-04-20 |
2007-06-16 |
Astrazeneca Ab |
Novel compounds
|
|
MX2008001067A
(es)
|
2005-08-01 |
2008-03-19 |
Astrazeneca Ab |
Derivados de piperidina novedosos como moduladores de receptor de quimioquina utiles para el tratamiento de enfermedades respiratorias.
|
|
TW200738635A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
RU2442771C2
(ru)
|
2005-08-08 |
2012-02-20 |
Арджента Дискавери Лтд |
Производные бицикло[2,2,1]гепт-7-иламина и их применения
|
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
|
TW200738659A
(en)
|
2005-08-29 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
|
US20090182033A1
(en)
|
2005-12-16 |
2009-07-16 |
Argenta Discovery Ltd. |
Cyclic Amine Derivatives and Their Uses
|
|
EP2013172A4
(en)
|
2006-04-24 |
2010-08-04 |
Astrazeneca Ab |
NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE
|
|
KR20090030347A
(ko)
|
2006-07-19 |
2009-03-24 |
아스트라제네카 아베 |
신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도
|
|
WO2008017827A2
(en)
|
2006-08-08 |
2008-02-14 |
Argenta Discovery Limited |
Azole and thiazole derivatives and their uses
|
|
GB0702384D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
Chemical compounds
|
|
WO2008023157A1
(en)
|
2006-08-21 |
2008-02-28 |
Argenta Discovery Limited |
Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
|
|
EP1894568A1
(en)
|
2006-08-31 |
2008-03-05 |
Novartis AG |
Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
|
|
TW200825084A
(en)
*
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
WO2008059239A1
(en)
|
2006-11-14 |
2008-05-22 |
Astrazeneca Ab |
Novel compounds 514
|
|
WO2008075006A1
(en)
|
2006-12-19 |
2008-06-26 |
Astrazeneca Ab |
Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
|
|
CA2672446A1
(en)
|
2006-12-19 |
2008-06-26 |
Astrazeneca Ab |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
|
TW200833670A
(en)
|
2006-12-20 |
2008-08-16 |
Astrazeneca Ab |
Novel compounds 569
|
|
WO2008096093A1
(en)
|
2007-02-06 |
2008-08-14 |
Argenta Discovery Ltd. |
Oxazole and thiazole derivatives and their uses
|
|
WO2008096094A1
(en)
|
2007-02-06 |
2008-08-14 |
Argenta Discovery Ltd. |
Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
|
|
GB0702385D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
WO2008096149A2
(en)
|
2007-02-07 |
2008-08-14 |
Argenta Discovery Ltd |
Napadisylate salt of a muscarinic m3 antagonist
|
|
GB0702382D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New salt
|
|
GB0702413D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New chemical compounds
|
|
WO2008096129A1
(en)
|
2007-02-07 |
2008-08-14 |
Argenta Discovery Ltd |
Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
|
|
GB0702416D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
GB0702414D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
Oxazole and thiazole derivatives and their uses 2
|
|
GB0702457D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination 666
|
|
GB0702456D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination
|
|
EP2121688A1
(en)
|
2007-02-15 |
2009-11-25 |
Argenta Discovery Ltd |
Heterocyclic derivatives as m3 muscarinic receptors
|
|
GB0704000D0
(en)
|
2007-03-01 |
2007-04-11 |
Astrazeneca Ab |
Salts 670
|
|
WO2008149053A1
(en)
|
2007-06-08 |
2008-12-11 |
Argenta Discovery Ltd. |
Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
|
|
WO2008149110A1
(en)
|
2007-06-08 |
2008-12-11 |
Argenta Discovery Limited |
Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
|
|
WO2009098455A1
(en)
|
2008-02-06 |
2009-08-13 |
Astrazeneca Ab |
2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
|
|
PL2242759T3
(pl)
|
2008-02-06 |
2013-06-28 |
Astrazeneca Ab |
Związki
|
|
WO2009098453A1
(en)
|
2008-02-06 |
2009-08-13 |
Astrazeneca Ab |
Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
|
|
GB0808707D0
(en)
|
2008-05-13 |
2008-06-18 |
Argenta Discovery Ltd |
New compounds 275
|
|
CN102908624A
(zh)
|
2008-05-13 |
2013-02-06 |
阿斯利康(瑞典)有限公司 |
包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
|
|
JP4837800B2
(ja)
|
2008-05-13 |
2011-12-14 |
アストラゼネカ・アクチエボラーグ |
ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
|
|
GB0808709D0
(en)
|
2008-05-13 |
2008-06-18 |
Astrazeneca Ab |
New combination 295
|
|
GB0808708D0
(en)
|
2008-05-13 |
2008-06-18 |
Astrazeneca Ab |
New compounds 274
|
|
WO2009153536A1
(en)
|
2008-06-17 |
2009-12-23 |
Argenta Discovery Limited |
1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
|
|
GB0811100D0
(en)
|
2008-06-17 |
2008-07-23 |
Astrazeneca Ab |
New combination
|
|
GB0811099D0
(en)
|
2008-06-17 |
2008-07-23 |
Astrazeneca Ab |
New combination 376
|
|
WO2010015792A1
(en)
|
2008-08-06 |
2010-02-11 |
Argenta Discovery Limited |
Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
|
|
CA2733449A1
(en)
|
2008-08-12 |
2010-02-18 |
Astrazeneca Ab |
2-hydroxy-ethanesulfonate salt
|
|
GB0814729D0
(en)
|
2008-08-12 |
2008-09-17 |
Argenta Discovery Ltd |
New combination
|
|
GB0814728D0
(en)
|
2008-08-12 |
2008-09-17 |
Argenta Discovery Ltd |
New combination
|
|
WO2010018352A1
(en)
|
2008-08-12 |
2010-02-18 |
Argenta Discovery Limited |
Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
|